# Jiabei Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jiabei-biologics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.shellbiotech.com
- Total disclosed funding: $16M
- Latest round: Series A (Nov 11, 2021)
- Investors on record: 3

## About

Established in 2017 and based in Shanghai, China, Shanghai Jiabei Biomedical Technology Co., Ltd, trading as Jiabei Biologics or Shell BioTech, is a biomedical technology developer that focuses on biopharmaceutical technology development and CDMO technical services. The company's R&D team has more than 120 employees. The company's management team comes from CDMO companies such as WuXi AppTec Group and RuiZhi. It has 6 R&D technical service platforms, 4500 square meters R&D center, and 8000 square meters cGMP production base. In 2020 the new laboratory in Zhangjiang Medical Valley was put into operation, and in 2022 the pharmaceutical GMP factory was officially put into operation. In September 2025, the firm closed a round of venture funding from Meihong Capital.

The company engages in the development of biopharmaceutical technology. It provides services such as CDMO for biological drugs, analysis and testing of macromolecules, development evaluation of finished drugs, and microbial fermentation platform. Macromolecule analysis and testing services include activity analysis, protein characterization, physical and chemical analysis and stability testing services.

The company generates revenue through the sales of its biopharmaceutical drugs.

## Funding rounds

- Series A, Nov 11, 2021, $16M — Cybernaut Investment Group, Hangzhou Value-added Investment Management
- Angel, Jan 21, 2019 — GoldHold Wisdom Venture Capital

## Investors

- GoldHold Wisdom Venture Capital (https://capitalatlas.ai/funds/goldhold-wisdom-venture-capital) — Angel
- Cybernaut Investment Group (https://capitalatlas.ai/funds/cybernaut-investment-group) — Series A
- Hangzhou Value-added Investment Management — Series A